In Re: Novartis and Par Antitrust Litigation

Case Number:  1:18-cv-4361
Court:  Southern District of New York
Judge:  Alvin K. Hellerstein
Status:  Settled

Garwin Gerstein & Fisher LLP was named lead class counsel on behalf of a class of direct purchasers of brand or generic Exforge tablets. Defendants are Novartis Pharmaceuticals Corp. and Novartis AG (collectively, “Novartis”). Plaintiffs allege that Defendants violated the Sherman Act when Novartis and its generic competitor, Par Pharmaceutical, Inc., entered into an anticompetitive reverse payment license agreement delaying generic competition for Exforge, thereby maintaining the price of Exforge at supra-competitive levels, and overcharging plaintiffs and members of the class. Plaintiffs are seeking overcharge damages incurred by the class caused by Defendants’ misconduct. 

Click document titles to open them.


  1. Complaint
  2. Motion for Certification of a Settlement Class, Appointment of Class Counsel, Preliminary Approval of Proposed Settlement with Novartis Pharmaceuticals Corporation and Novartis AG, Approval of the Form and Manner of Notice to the Class, and a Proposed Schedule for a Fairness Hearing
  3. Memorandum of Law in Support of Motion for Certification of a Settlement Class, Appointment of Class Counsel, Preliminary Approval of Proposed Settlement with Novartis Pharmaceuticals Corporation and Novartis AG, Approval of the Form and Manner of Notice to the Class, and a Proposed Schedule for a Fairness Hearing
  4. Order Granting Motion for Certification of a Settlement Class, Appointment of Class Counsel, Preliminary Approval of Proposed Settlement with Novartis Pharmaceuticals Corporation and Novartis AG, Approval of the Form and Manner of Notice to the Class, and a Proposed Schedule for a Fairness Hearing
  5. Notice to Class
© Garwin Gerstein & Fisher LLP 2023  
88 Pine Street 10th Floor,
New York, NY 10005
Attorney Advertising  
Disclaimer   Diversity Policy